Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using genetics to understand the role of antihypertensive drugs modulating angiotensin-converting enzyme in immune function and inflammation.

British journal of clinical pharmacology - 1 Apr 2021

Zhao Jie V, Schooling C Mary, Leung Gabriel M

Abstract excerpt

AIM: Angiotensin-converting enzyme 2 (ACE 2) is the binding domain for severe acute respiratory syndrome coronavirus (SARS-CoV) and SARSCoV-2. Some antihypertensive drugs affect ACE2 expression or activity (ACE inhibitors and angiotensin II receptor blockers [ARBs]), suggesting use of other hypertensives might be preferable, such as calcium channel blockers (CCBs). Given the limited evidence, the International...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Angiotensin-Converting Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antihypertensive Agents

Share to Immunity

Share to Lymphocytes

Share to Mendelian Randomization Analysis

Share to Neutrophils

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 33025652
DOI: 10.1111/bcp.14572
PMCID: PMC7675404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using genetics to understand the role of antihypertensive drugs modulating angiotensin-converting enzyme in immune function and inflammation.PMID 33025652Read ↗

ACE inhibition and cardiometabolic risk factors, lung <i>ACE2</i> and <i>TMPRSS2</i> gene expression, and plasma ACE2 levels: a Mendelian randomization studySemantic proximity Read ↗

Hypertension and renin-angiotensin system blockers are not associated with expression of Angiotensin Converting Enzyme 2 (ACE2) in the kidneySemantic proximity Read ↗

Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseasesSemantic proximity Read ↗

Using Mendelian randomization study to assess the renal effects of antihypertensive drugsSemantic proximity Read ↗

Pharmacogenetics of antihypertensive treatment.Semantic proximity Read ↗

Genetic proxies for antihypertensive drugs and mental disorders: Mendelian randomization study in European and East Asian populationsSemantic proximity Read ↗

ARB/ACEI use and severe COVID-19: a nationwide case-control studySemantic proximity Read ↗

Pharmacogenomics And Hypertension: Current InsightsSemantic proximity Read ↗

Association of Angiotensin Converting Enzyme Phenotypes and Polymorphisms with Clinical Outcomes in SARS-CoV2 Patients with Hypertension in an Urban Emergency Department.Semantic proximity Read ↗

Antihypertensive medication uses and serum ACE2 levelsSemantic proximity Read ↗

Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cellsSemantic proximity Read ↗

The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.